Patent US4393049A successfully refreshed from Google Patents.
US4393049A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment for obesity
Assignee: Efamol Ltd
•
Filing: 1981-06-10
•
Granted: 1983-07-12
•
Expires: 2001-06-10
Abstract
Abstract Use of γ-linolenic acid and related materials alone or with zinc or β-lactam antibiotics to treat obesity.
Inventors
- 👤 David F. Horrobin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 13:41
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61K31/542; A61K31/545; A61K31/41; A61K31/425; A61K31/429; A61K31/43; A61K33/00; A61K33/24; A61K33/30
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
31 words
A method of treating obesity comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof.
Claim 2
Independent Claim
31 words
A method of treating obesity comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof.
Claim 3
Dependent Claim
27 words
A method according to claim 1, wherein the daily amount of γ-linolenic or dihomo-γ-linolenic acid or derivatives thereof is 0.05 to 10 g calculated as γ-linolenic acid.
Claim 4
Dependent Claim
28 words
A method according to claim 1, wherein the daily amount of γ-linolenic or dihomo-γ-linolenic acid or derivatives thereof is from 0.1 to 5 g calculated as γ-linolenic acid.
Claim 5
Independent Claim
53 words
A method of treating obesity comprising administering to a person suffering therefrom an effective amount of (a) γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) a conjoint amount of a material influencing the 1-series/2-series PG balance in the body in favour of 1-series PG's.
Claim 6
Independent Claim
53 words
A method of treating obesity comprising administering to a person suffering therefrom an effective amount of (a) γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) a conjoint amount of a material influencing the 1-series/2-series PG balance in the body in favour of 1-series PG's.
Claim 7
Dependent Claim
14 words
A method according to claim 4, wherein said material (b) is physiologically assimilable zinc.
Claim 8
Dependent Claim
34 words
A method according to claim 5, wherein the daily amount of the active components is from 0.05 to 10 g of (a) calculated as γ-linolenic acid and from 2.5 to 800 mg of (b).
Claim 9
Dependent Claim
34 words
A method according to claim 5, wherein the daily amount of the active components is from 0.1 to 5 g of (a) calculated as γ-linolenic acid and from 10 to 80 mg of (b).
Claim 10
Dependent Claim
14 words
A method according to claim 4, wherein said material (b) is a β-lactam antibiotic.
Claim 11
Dependent Claim
18 words
A method according to claim 8, wherein said antibiotic is a natural or semi-synthetic penicillin or cephalosporin antibiotic.
Claim 12
Dependent Claim
25 words
A method according to claim 8, wherein said antibiotic is selected from pencillin G, penicillin N, penicillin V, cephalothin, ampicillin, amoxycillin, cloxacillin, cephalexin and cephaloglycin.
Claim 13
Dependent Claim
35 words
A method according to claim 8, 9 or 10, wherein the daily amount of the active components is from 0.05 to 10 g (a) calculated as γ-linolenic acid and 0.5 to 3 g of (b).
Claim 14
Dependent Claim
36 words
A method according to claim 8, 9 or 10, wherein the daily amount of the active components is from 0.1 to 5 g (a) calculated as γ-linolenic acid and from 0.5 to 3 g of (b).
Claim 15
Independent Claim
46 words
A method of treating obesity comprising administering to a person suffering therefrom an effective amount of (a) γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and conjoint amounts of (b) physiologically assimilable zinc, and (c) a β-lactam antibiotic.
Claim 16
Independent Claim
46 words
A method of treating obesity comprising administering to a person suffering therefrom an effective amount of (a) γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and conjoint amounts of (b) physiologically assimilable zinc, and (c) a β-lactam antibiotic.
Claim 17
Dependent Claim
21 words
A method according to claim 5 or 13 wherein the zinc is present as zinc oleate, zinc γ-linolenate or zinc dihomo-γ-linolenate.
References Cited (Backward Citations)
US1926745A
Cited
GB1391449A
Cited
US4237118A
Cited
US3923982A
Cited
US4034099A
Cited
US4058594A
Cited
FR2272684A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-07-11 | 1987-01-10 | 1987-07-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-07-11 | 1991-01-10 | 1991-07-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-07-11 | 1995-01-10 | 1995-07-12 | $7700.00 | Window Closed / Lapsed |